Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cyclin D linked to breast cancer transition

This article was originally published in Clinica

Executive Summary

Cyclin D regulation may define a major transition from a benign state to commitment to carcinoma in human breast cancer. Researchers at the US National Cancer Institutes in Bethesda, Maryland undertook comparative in situ hybridisation studies on 94 breast biopsy lesions of four different types: those conferring no or slightly increased risk for breast cancer; atypical ductal hyperplasias (ADHs); ductal carcinomas in situ (DCIS), ranging from noncomedo forms to comedo forms; and invasive breast cancers. (Nature Medicine, December.)

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT094524

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel